The authors concluded, "There is high-certainty evidence that HPV vaccines protect against cervical precancer in adolescent girls and young women aged 15 to 26," while also indicated that future studies should have long-term follow-up.
There are currently no approved treatments or vaccines available for chikungunya, a virus transmitted through mosquito bites.
The researchers found that even relatively low-efficacy influenza vaccines can have a high impact, especially with optimal distribution across age groups. In order to minimize mortality and DALYs, the optimal distribution of the vaccine uptake shifts toward the elderly as vaccine efficacy declines.
The sBLA included clinical data from a Phase 4 study that enrolled nearly 2000 children and assessed the safety and immunogenicity of the 0.5mL dose.
The Breakthrough designation was based on data from Phase 2 studies which assessed the safety and efficacy of the vaccine in this patient population.
MF59 adjuvanted, quadrivalent influenza vaccine (aQIV) was found to be more efficacious in preventing influenza than a non-adjuvanted conventional influenza vaccine in children aged 6 through 23 months.
The researchers enrolled 25 platinum-pretreated, immunotherapy-naïve patients with recurrent advanced epithelial ovarian cancer (EOC) for the trial.
Zika virus shown to be of moderate to high efficacy in eliminating prenatal infections.
From January to March 2017, the researchers distributed a cross-sectional online survey to all physicians in the Division of General Internal Medicine and Clinical Innovation at NYULH, across 5 different practice settings. A total of 138 (out of 530) responded (26%).
The researchers found that for a base-case vaccine efficacy of 75% and vaccination coverage of 90%, immunizing females aged 9 to 49 years would reduce the incidence of prenatal infections by at least 94%, depending on the country-specific Zika attack rate.
The researchers found that both vaccines were well tolerated in both 6- to 8-year-olds and 9- to 17-year-olds. There were no vaccine-related adverse events in the 6 months of follow-up.
This schedule indicates the recommended age groups and medical indications for routine administration of currently licensed vaccines for persons 19 years and older.
This schedule indicates the recommended ages for routine administration of currently licensed childhood vaccines for children 0-18 years of age.
Recommended vaccination schedule for HIV-infected children ages 0 to 6 years old.
The researchers found that vaccine-derived immune protection against mumps waned on average 27 years after vaccination. There was no evidence of heterologous virus genotypes contributing to changes in vaccine effectiveness over time.
Infantile immunization rates were higher among children whose caregivers received compliance-linked incentives when compared to those who received only mobile phone reminders and those who received no intervention.
The researchers observed an increase in captured opportunities for HPV vaccination, from 46.9 to 63.3%. Centerline shift demonstrated special cause, with 8 consecutive points above the preintervention mean.
A catch-up immunization schedule for children 4 months to 18 years of age, including minimum intervals between doses of delayed immunizations.
The matched odds ratio for estimated cumulative antigen exposure through 23 months was not significant among children with versus those without non-vaccine-targeted infections from 24 through 47 months of age.
A greater effect of the intervention was seen for pediatric practices versus family medicine practices and in private practices versus public ones. According to reports from health care professionals, the most used and useful intervention components were communication training and the fact sheets.
For hepatitis B (≥3 doses), foreign-born adolescents had significantly lower coverage rates, 89.6% vs. 92.6% for U.S.-born adolescents, even after adjustments were made for demographic and socioeconomic factors.